Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:28:13.056Z.
Calculation as of: 2026-10-06T20:28:13.056Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69c6abe1898d62982c9f5472fcc208679ef9964d1dbc89e7ebe68f1e3eabf120
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2020-05-12.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Protara Therapeutics, Inc.
Market Cap
$143.60M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$143.84M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.28M
EV/EBITDA Ratio
N/A
TTM Avg
183.85x
3Y Avg
184.46x
5Y Avg
184.46x
Market Cap
$146.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $143.60M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $146.28M | N/A | 183.85x | 184.46x | 184.46x |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $139.04M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2020-05-12 | 46.09x |
| 2020-05-11 | 47.26x |
| 2020-05-08 | 45.99x |
| 2020-05-07 | 48.60x |
| 2020-05-06 | 49.21x |
| 2020-05-05 | 50.40x |
| 2020-05-04 | 48.42x |
| 2020-05-01 | 44.95x |
| 2020-04-30 | 45.89x |
| 2020-04-29 | 45.40x |
| 2020-04-28 | 44.91x |
| 2020-04-27 | 44.91x |
| 2020-04-24 | 44.85x |
| 2020-04-23 | 43.69x |
| 2020-04-22 | 42.65x |
| 2020-04-21 | 41.97x |
| 2020-04-20 | 41.87x |
| 2020-04-17 | 43.93x |
| 2020-04-16 | 44.52x |
| 2020-04-15 | 44.91x |
| 2020-04-14 | 44.95x |
| 2020-04-13 | 42.95x |
| 2020-04-09 | 41.59x |
| 2020-04-08 | 44.42x |
| 2020-04-07 | 43.44x |
| 2020-04-06 | 40.98x |
| 2020-04-03 | 43.03x |
| 2020-04-02 | 44.91x |
| 2020-04-01 | 45.40x |
| 2020-03-31 | 42.95x |
| 2020-03-30 | 40.20x |
| 2020-03-27 | 40.79x |
| 2020-03-26 | 41.00x |
| 2020-03-25 | 41.97x |
| 2020-03-24 | 44.91x |
| 2020-03-23 | 39.06x |
| 2020-03-20 | 43.44x |
